“Yes, they did,” Dr. Gilman finally said. He felt sick to his stomach. The safety monitoring committee was fielding multiple reports of vasogenic edema in patients. Although it was a secret, Martoma seemed, somehow, to be aware of it and was looking for confirmation, and Gilman had just given it to him. The trial clinicians were still debating whether the side effect was a sign of potential toxicity, of bapi’s effectiveness, or both. Gilman knew that he had crossed a line by disclosing it to Martoma. But he felt powerless to say no.
